Please assess the completion status of the following clinical trial:

Trial Title: A Safety and Efficacy Study of INC280 Alone, and in Combination With Erlotinib, Compared to Chemotherapy, in Advanced/Metastatic Non-small Cell Lung Cancer Patients With EGFR Mutation and cMET Amplification

Study Design Characteristics:
- Allocation: NON_RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE1
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Locally advanced or metastatic NSCLC~* EGFR mutation (L858R and /or ex19del)~* cMET amplification by FISH (GCN ≥ 6),~* Acquired resistance to EGFR TKI (1st or 2nd generation)~* ECOG performance status (PS) ≤ 1.~Exclusion Criteria:~* Prior treatment with 3rd generation TKI~* PhaseII : Prior treatment with any of the following agents:~  * Crizotinib, or any other cMET inhibitor or HGF-targeting inhibitor.~ * Concomitant EGFR TKI and platinum based chemotherapy as first line regimen.~ * Platinum-based chemotherapy as first line treatment

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- INC280 200mg BID + ERL 150mg QD (Type: EXPERIMENTAL): Subjects who took INC280 200mg twice a day (BID) in combination with erlotinib (ERL) 150mg one a day (QD)
- INC280 400mg BID + ERL 150mg QD (Type: EXPERIMENTAL): Subjects who took INC280 400mg twice a day (BID) in combination with erlotinib (ERL) 150mg one a day (QD)

Based on this trial design, predict the completion outcome and termination type (if applicable).